ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
S

ASH 2022: What Is Complete HLA Match in 2022?

By ASH 2022 Conference Coverage FEATURING Stephen Spellman
By ASH 2022 Conference Coverage FEATURING Stephen Spellman
178 views
January 4, 2023
1 Comment
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
MDS and MPN
18:24
ASH 2022 Conference Coverage

Ropeginterferon Alfa-2b vs. Standard Therapy for Low-Risk Pts With P…

Feat. T. Barbui
05:09
ASH 2022 Conference Coverage

MEDALIST Study: Multiple Episodes of Transfusion Independence With L…

Feat. U. Platzbecker
31:13
ASH 2022 Conference Coverage

Selected Updates in MDS

Feat. A. Zeidan
08:24
ASH 2022 Conference Coverage

Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Ne…

Feat. A. Vannucchi
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
03:41
ASH 2022 Conference Coverage

ASH 2022: Venetoclax Combined With Cladribine, Idarubicin, Cytarabin…

Feat. G. Borthakur
06:04
ASH 2022 Conference Coverage

ASH 2022 Real-World Validation of Molecular International Prognostic…

Feat. M. Della Porta
11:00
ASH 2022 Conference Coverage

ASH 2022: Management of Accelerated and Blast-Phase MPN

Feat. R. Rampal
10:14
ASH 2022 Conference Coverage

ASH 2022: Navitoclax and Ruxolitinib in JAKi-Naïve Patients With MF …

Feat. F. Passamonti
27:09
ASH 2022 Conference Coverage

ASH 2022: What Is Complete HLA Match in 2022?

Feat. S. Spellman
06:34
ASH 2022 Conference Coverage

ASH 2022 Outcomes of Patients With Accelerated/Blast-Phase MPNs in t…

Feat. A. Patel
09:54
ASH 2022 Conference Coverage

ASH 2022 Phase II Study of Myeloablative 8/8- or 7/8-Matched AlloSCT…

Feat. A. Hoover
06:06
ASH 2022 Conference Coverage

Synergistic Activity of Luspatercept and Erythroid Stimulating Agent…

Feat. R. Komrokji
06:55
ASH 2022 Conference Coverage

Luspatercept for Treatment of LR-MDS: Real World Data Replicates MED…

Feat. R. Komrokji
07:02
ASH 2022 Conference Coverage

ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-…

Feat. D. Sallman
10:30
ASH 2022 Conference Coverage

ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blin…

Feat. A. Zeidan
06:10
ASH 2022 Conference Coverage

Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safe…

Feat. J. Mascarenhas
08:11
ASH 2022 Conference Coverage

Validation of 2022 WHO & ICC Classifications in MDS - An Analysi…

Feat. S. Ball
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
11:40
ASH 2022 Conference Coverage

ASH 2022 Efficacy & Safety of Add-On Parsaclisib to Ruxolitinib …

Feat. A. Yacoub
08:57
ASH 2022 Conference Coverage

ASH 2022 Impact of Allelic State on Overall Survival in TP53-Mutant …

Feat. J. Bewersdorf
11:20
ASH 2022 Conference Coverage

Updated Results From the Momentum Phase 3 Study of Momelotinib vs. D…

Feat. A. Gerds